Tradeoffs

Charting the Uneven Progress in Medical School Diversity

Samantha Artiga discusses research showing how several racial and ethnic groups continue to be underrepresented in U.S. medical schools.

Read More

The Aducanumab Aftermath: The Payer

A costly new Alzheimer’s drug could wreak financial havoc on insurers, seniors and taxpayers.

Read More

The Aducanumab Aftermath: The Patient

One patient shares her hopes and concerns about a costly new Alzheimer’s drug.

Read More

“The Aducanumab Aftermath: The Doctor Transcript”

‘The Aducanumab Aftermath: The Doctor’ Transcript June 22, 2021 Note: This transcript has been created with a combination of machine ears and human eyes. There may be small differences between this document and the audio version, which is one of many reasons we encourage you to listen to the episode! Listen in Apple Podcasts Listen on…

Read More

The Aducanumab Aftermath: The Doctor

One doctor grapples with questions about a controversial new Alzheimer’s drug’s safety and efficacy.

Read More

Babies, Boats & Abstracts: An Insider’s Guide to Health Policy Conferences

Health economist Kosali Simon shares conference tips, stories and abstracts she’s excited for at AcademyHealth and ASHEcon.

Read More

How Can Health Policy Researchers Measure Structural Racism?

Katy Backes Kozhimannil explores a review of how the impacts of structural racism have been studied in reproductive health.

Read More

Drilling Into a Dentist’s COVID Roller Coaster Ride

From the fear of shutting down to the exhaustion of reopening and the missed appointments in between.

Read More

What NASCAR Can Teach Us About Pollution and Social Determinants of Health

Kosali Simon breaks down research that uses NASCAR’s switch to unleaded gas to explore the impact of pollution on kids’ cognitive development.

Read More

The FDA’s Pressure-Packed Alzheimer’s Drug Decision

The FDA weighs whether to approve a controversial new Alzheimer’s drug.

Read More